Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Scodes

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Psychiatric Services (Washington, D.C.)|June 2, 2021
Predictors of Persistent Symptoms in People in Coordinated Specialty Care Services for Early Psychosis in New York StateJuliana Zambrano, Jennifer Scodes, Leslie A Marino, et al.
The American Journal of Psychiatry|December 2, 2017
Disability Enrollment in a Community-Based Coordinated Specialty Care ProgramJennifer Humensky, Jennifer Scodes, Melanie Wall, et al.
Addictive Behaviors|July 4, 2020
Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adultsAngela M Haeny, LaTrice Montgomery, A Kathleen Burlew, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 2, 2017
Association of Obstructive Sleep Apnea with Episodic Memory and Cerebral Microvascular Pathology: A Preliminary StudyNancy A Kerner, Steven P Roose, Gregory H Pelton, et al.
Alcoholism, Clinical and Experimental Research|July 4, 2020
Reduction in World Health Organization Risk Drinking Levels and Cardiovascular DiseaseJustin Knox, Jennifer Scodes, Katie Witkiewitz, et al.
Journal of Addiction Medicine|February 11, 2020
Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use DisorderMatisyahu Shulman, Sean X Luo, Aimee N C Campbell, et al.
Journal of Substance Abuse Treatment|June 12, 2021
Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials NetworkLaTrice Montgomery, Theresa Winhusen, Jennifer Scodes, et al.
The American Journal of Psychiatry|January 21, 2021
The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013Dvora Shmulewitz, Efrat Aharonovich, Katie Witkiewitz, et al.
Psychiatric Services (Washington, D.C.)|February 3, 2021
Clients' Preferences for Family Involvement and Subsequent Family Contact Patterns Within OnTrackNY Early Psychosis ServicesNev Jones, Cale Basaraba, Sarah Piscitelli, et al.
The American Journal of Drug and Alcohol Abuse|August 28, 2020
Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in CaucasiansMatthew Randesi, John Rotrosen, Edward V Nunes, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Psychiatric Services (Washington, D.C.)|June 2, 2021
Predictors of Persistent Symptoms in People in Coordinated Specialty Care Services for Early Psychosis in New York StateJuliana Zambrano, Jennifer Scodes, Leslie A Marino, et al.
The American Journal of Psychiatry|December 2, 2017
Disability Enrollment in a Community-Based Coordinated Specialty Care ProgramJennifer Humensky, Jennifer Scodes, Melanie Wall, et al.
Addictive Behaviors|July 4, 2020
Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adultsAngela M Haeny, LaTrice Montgomery, A Kathleen Burlew, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 2, 2017
Association of Obstructive Sleep Apnea with Episodic Memory and Cerebral Microvascular Pathology: A Preliminary StudyNancy A Kerner, Steven P Roose, Gregory H Pelton, et al.
Alcoholism, Clinical and Experimental Research|July 4, 2020
Reduction in World Health Organization Risk Drinking Levels and Cardiovascular DiseaseJustin Knox, Jennifer Scodes, Katie Witkiewitz, et al.
Journal of Addiction Medicine|February 11, 2020
Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use DisorderMatisyahu Shulman, Sean X Luo, Aimee N C Campbell, et al.
Journal of Substance Abuse Treatment|June 12, 2021
Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials NetworkLaTrice Montgomery, Theresa Winhusen, Jennifer Scodes, et al.
The American Journal of Psychiatry|January 21, 2021
The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013Dvora Shmulewitz, Efrat Aharonovich, Katie Witkiewitz, et al.
Psychiatric Services (Washington, D.C.)|February 3, 2021
Clients' Preferences for Family Involvement and Subsequent Family Contact Patterns Within OnTrackNY Early Psychosis ServicesNev Jones, Cale Basaraba, Sarah Piscitelli, et al.
The American Journal of Drug and Alcohol Abuse|August 28, 2020
Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in CaucasiansMatthew Randesi, John Rotrosen, Edward V Nunes, et al.
Pageof 5